INTRODUCTION {#sec1-1}
============

Large number of new drugs are introduced into the market every day.\[[@ref1]\] Pharmaceutical companies use drug promotional literatures (DPLs) as a major marketing tool to promote their new drugs.\[[@ref2]\] DPLs are claimed to provide vital drug information and are being utilized to convince health professionals to prescribe the new drug.\[[@ref3][@ref4][@ref5]\] Many a times, it is the only source on which treating physicians depend on for updating their knowledge about the existing and novel drugs.\[[@ref6]\] In 2005, a pharmaceutical industry in the USA has spent more than 30 billion dollars in marketing and promoting to enlighten the clinicians about their products.\[[@ref7]\] Such marketing influences clinician\'s prescribing behavior with or without benefitting the patient.

According to the World Health Organization (WHO), medicinal drug promotion is defined as "all informational and persuasive activities by manufactures and distributors, the effect of which is to induce the prescription, supply, purchase, and/or use of medicinal drugs."\[[@ref8][@ref9]\] Therefore, for the rational use of drugs, the WHO has laid down ethical criteria for medicinal drug promotion and has recommended pharmaceutical industries to implement these guidelines.\[[@ref3]\] Organization of Pharmaceutical Producers of India, a self-regulatory code of pharmaceutical marketing practices, effective from December 2012, stated seven criteria which DPLs should follow.\[[@ref10]\] Few studies have observed that information provided in DPLs are varying with the code of ethics.\[[@ref11][@ref12]\] This can affect the drug prescription, utilization, and sometimes can be irrational. Hence, this study was conducted to critically assess the accuracy of the promotional drug literature using the WHO guidelines.

METHODS {#sec1-2}
=======

An observational study was conducted by the Department of Pharmacology at R.L. Jalappa Hospital and Research Centre attached to Sri Devaraj Urs Medical College, Kolar, India, for a period of 6 months from March to August 2014, after the protocol was approved by the Institutional Ethics Committee. DPLs in the form of flyers, leaflets, and brochures were collected from various outpatient departments which were available in the hospital through medical representatives. Collected DPLs were assessed as per the WHO guidelines. Literature promoting medicinal devices and equipment (insulin pump, blood glucometer, and orthopedic prosthesis), ayurvedic medications, drug monographs, reminder advertisements, drugs' name list, and literature promoting more than one drug or more than one fixed drug combination were excluded.

The following are the WHO criteria to be followed by pharmaceutical industries for the completeness of DPL:\[[@ref13]\]

The names of the active ingredients using either international nonproprietary names or the approved generic names of the drugThe brand nameContent of active ingredient per dosage form or regimenName of other ingredients known to cause problems, i.e., adjuvantApproved therapeutic usesDosage form or regimenSide effects and major adverse drug reactionPrecautions, contraindications, and warningsMajor interactionsName and address of the manufacturer or distributorReference to scientific literature as appropriate.

The DPLs were also analyzed for additional information such as various pictures printed, cost mentioned, and source and year of references used to defend the DPL claims. Descriptive statistics were used to analyze the data. The data were expressed as percentage.

RESULTS {#sec1-3}
=======

A total of 200 DPLs were collected and analyzed, which revealed 134 (67%) were single drug formulation and 66 (33%) were fixed dose combination. [Figure 1](#F1){ref-type="fig"} represents the most commonly promoted drug categories/or system wise. The extent to which DPLs followed the WHO criteria is shown in [Table 1](#T1){ref-type="table"}. Drug cost was revealed only in 12 (6%) brochures. Pictures occupied considerable amount of space on all brochures. DPLs depicted photographs of drug formulation, disease or organ, healthy/depressed men and women, and others as shown in [Figure 2](#F2){ref-type="fig"}. Only 63 (31.5%) DPLs had relevant pictures of drugs being promoted and 137 (68.5%) had irrelevant representation in the form of car, women, men, and cartoons occupying major area. The pharmacological properties were represented in the form of graphs in 59 (29.5%) DPLs. The quality of paper used for DPLs were durable and the text was legible.

![Most commonly promoted drug categories/or system-wise. Miscellaneous: includes hormonal agents, immunomodulators, and antihistamines. CNS: Central nervous system; GITs: Gastrointestinal tract system; NSAIDs: Non-steroidal anti-inflammatory drugs; RS: Respiratory system; CVS: Cardiovascular system; DPLs: Drug promotional literatures](JRPP-5-162-g001){#F1}
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Analysis of drug promotional literatures according to the World Health Organization criteria (*n*=200)
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![Types of pictures depicted on DPLs. DPLs: Drug promotional literatures](JRPP-5-162-g003){#F2}

In 133 DPLs, 267 references were mentioned \[[Table 2](#T2){ref-type="table"}\]. Majority of references were quoted from journal articles, of which references published after 2010 were only 65 (32.5%) as represented in [Table 2](#T2){ref-type="table"}. Ten out of 11 criteria of the WHO were followed by 30 (15%) DPLs. A total of 131 (69%) brochures satisfied 50% of the WHO criteria. None of the brochures adhered to all the criteria.
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Source of various references in the drug promotional literatures
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DISCUSSION {#sec1-4}
==========

Marketing new drugs to physicians is an important strategy adopted by pharmaceutical companies.\[[@ref14]\] DPLs are sometimes the only source about new drugs/new indications for old drugs. In our study, it was observed that none of the DPLs fulfilled all the criteria laid down by the WHO guidelines. A similar finding was reported in other studies.\[[@ref2][@ref3][@ref6][@ref8]\] This suggests that drug promotional companies are more involved in establishing a commercial relationship with the treating physicians wherein ethical educational aspect is compromised.\[[@ref2]\] In the present study, 33% of DPLs promoted fixed drug combination, hence the physicians should consider the rationality of the drug combination before prescribing.

Cardiovascular agents, antidiabetic drugs, and antimicrobials were among the top three groups of drugs being promoted, indicating that pharmaceutical companies are targeting diseases which are widely prevalent. This finding was in concordance with a study conducted in Mumbai.\[[@ref1]\] Treating physicians should be highly cautious while prescribing the drugs based on information given in DPLs to avoid irrational prescription, higher incidence of drug resistance, adverse effects, and to reduce the cost incurred by patients.\[[@ref1][@ref15]\]

It was observed that most of the DPLs had mentioned brand name, approved generic name, and active ingredient per dosage form, which is similar to a study conducted in Nepal.\[[@ref11]\] In our study, none of the brochures had mentioned other ingredients that are known to cause problems. We observed that majority of DPLs quoted dosage schedule and therapeutic indications, but did not stress on adverse drug reactions, precautions, contraindications, and interactions. The above criteria are certainly necessary for the care of the patient and also manage physician time from looking into other source of information. Similar findings were observed in other studies.\[[@ref2][@ref3][@ref6][@ref12][@ref16][@ref17]\]

All the brochures were colorful and attractive, but had irrelevant pictures related to the drugs being promoted. DPLs had used nonspecific representations occupying major area, which could have been utilized appropriately for listing various properties of drugs, other studies have reported similar finding.\[[@ref2][@ref3][@ref8]\] In this study, it was observed that unsubstantiated claims were made in the brochures regarding efficacy and safety. Recent references were mentioned in very few DPLs, but this is essential for updating the clinicians so as to expand their existing knowledge and practice evidence-based medicine.

In view of this study, it is of utmost importance for the treating physician to critically evaluate any source of drug information based on the established guidelines before accepting them as scientific piece of information. Regional Ethics Committee in various metropolitan cities in India collect complaints about unethical drug promotion and report the same to the Drug Controller General of India to take necessary legal steps to regulate pharmaceutical companies to publish DPLs fulfilling the WHO criteria.\[[@ref2][@ref3][@ref8][@ref9]\]

Sixty-nine percent of the advertisements satisfied only half of the WHO criteria for rational drug promotion. Hence, the treating physicians should learn the art of analyzing DPL to provide quality care for the patients.
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